Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression

Liver International

Volumn 25, Issue 1, 2005, Pages 148-152

  Dou, Jian ^a   Iwashita, Yukio ^a   Sasaki, Atsushi ^a   Kai, Seiichiro ^a   Hirano, Seitaro ^a   Ohta, Masayuki ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Consensus interferon; Dihydropyrimidine dehydrogenase; Reverse transcription polymerase chain reaction; WST 1

Indexed keywords

CONSENSUS INTERFERON; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; INTERFERON TYPE I, RECOMBINANT; LIVER NEOPLASMS; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 14544283281     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01030.x     Document Type: Article

References (22)

1. Frasci G, Leone F, Monaco M, et al. 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. Dis Colon Rectum 1994; 37: 643-50.
2. Lee K H, Lee J S, Suh C, et al. Combination of 5-fluorouracil and recombinant interferon alpha-2B in advanced gastric cancer. A phase I study. Am J Clin Oncol 1992; 15: 141-5.
3. Murphy B R, Rynard S M, Eeinhorn L H, Loehrer P J. A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study. Invest New Drugs 1992; 10: 225-30.
4. Tanaka N, Ohoida J, Matuno T, et al. Response of adenosquamous carcinoma of the pancreas to interferon-alpha, tumor necrosis factor-alpha and 5-fluorouracil combined treatment. Anticancer Res 1994; 14: 2739-42.
5. Miyamoto A, Umeshita K, Sakon M, et al. Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 2000; 15: 1447-51.
6. Tanaka-Nozaki M, Onda M, Tanaka N, Kato S. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin Cancer Res 2001; 7: 2783-7.
7. Kirihara Y, Yamamoto W, Toge T, Nishiyama M. Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 1999; 14: 551-6.
8. Morita T, Tokue A. Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol 1999; 44: 91-6.
9. Ishida Y, Kawakami K, Tanaka Y, et al. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 2002; 22: 2805-9.
10. Wadler S, Horowitz R, Mao X, Schwartz E L. Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks. Cancer Chemother Pharmacol 1996; 38: 529-35.
11. Alberti A. Interferon Alfacon-1: a novel interferon for the treatment of chronic hepatitis C. BioDrugs 1999; 12: 343-57.
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
13. Scudiero D A S R, Paull K D, Monks A, Tierney S, Nofziger T H, Currens M J, Seniff D, Boyd M R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-33.
14. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs 2002; 16: 261-81.
15. Schwartz E L, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995; 270: 19073-7.
16. Presant C A, Wolf W, Waluch V, et al. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: an in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. J Clin Oncol 2000; 18: 255-61.
17. Heggie G C, Sommadossi J P, Cross D S, Huster W J, Diasio R B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
18. Lu A, Zhang R, Diasio R B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992; 267: 17102-9.
19. Hirano Y, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. Cancer Chemother Pharmacol 2003; 51: 29-35.
20. Milano G, Fischel J L, Etienne M C, et al. Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines. Cancer Chemother Pharmacol 1994; 34: 147-52.
21. Yamada H, Ichikawa W, Uetake H, et al. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clin Colorectal Cancer 2001; 1: 169-73; discussion 74.
22. Klein S B, Blatt L M, Taylor M W. Cell surface binding characteristics correlate with consensus type I interferon enhanced activity. J Interferon Cytokine Res 1996; 16: 1-6.